Head of Early Assets, Cell Therapy
AstraZeneca
About this role
The Head of Early Assets, Cell Therapy at AstraZeneca will shape the early cell therapy pipeline from preclinical through early clinical development, translating scientific innovation into commercial strategy and long-term patient impact. The role sits on the Oncology Business Unit leadership team and partners across R&D, Global Product Teams, Business Development, Medical, Market Access, Finance, and priority markets to build target product profiles and scalable go-to-market pathways.
Skills
Qualifications
About AstraZeneca
astrazeneca.comDigital Biology is part of AstraZeneca, a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines. The Digital Biology organization applies data science, computational biology, AI, and software engineering to accelerate drug discovery and translational research across therapeutic areas.
About AstraZeneca
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Leadership Team
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
Unlock Company Insights
View leadership team, funding history,
and employee contacts for AstraZeneca.
Salary
$270k – $405k
per year
More jobs at AstraZeneca
Similar Jobs
Senior Field Application Scientist EMEA, Cell Therapy & Regulatory Markets
Cell Signaling Technology
Cell Therapy Account Management - North Florida
Iovance Biotherapeutics
Intern- Product Development, Cell Biology
AskBio
Marketing Director Cell Therapy (m/f/d)
Gilead Sciences
Scientist R&D (Cell Culture)
Cepheid
Global Medical Director – Cell & Gene Therapy
Novartis